블로그

• [FDA, 200610] 옵디보, 식도편평세포암종 허가 On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy blog.naver.com · 2020.06.14